Cargando…

Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial

BACKGROUND: In patients with COVID-19, granulocyte-macrophage colony stimulating factor (GM-CSF) might be a mediator of the hyperactive inflammatory response associated with respiratory failure and death. We aimed to evaluate whether mavrilimumab, a monoclonal antibody to the GM-CSF receptor, would...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cremer, Paul C, Abbate, Antonio, Hudock, Kristin, McWilliams, Carla, Mehta, Jinesh, Chang, Steven Y, Sheng, Calvin C, Van Tassell, Benjamin, Bonaventura, Aldo, Vecchié, Alessandra, Carey, Brenna, Wang, Qiuqing, Wolski, Katherine E, Rajendram, Prabalini, Duggal, Abhijit, Wang, Tisha S, Paolini, John F, Trapnell, Bruce C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2021
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7969143/ https://www.ncbi.nlm.nih.gov/pubmed/33754144 http://dx.doi.org/10.1016/S2665-9913(21)00070-9

Ejemplares similares

Targeting GM-CSF in COVID-19 Pneumonia: Rationale and Strategies
por: Bonaventura, Aldo, et al.
Publicado: (2020)

GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study
por: De Luca, Giacomo, et al.
Publicado: (2020)

Colchicine for COVID-19: targeting NLRP3 inflammasome to blunt hyperinflammation
por: Bonaventura, Aldo, et al.
Publicado: (2022)

Mavrilimumab for severe COVID-19
por: Khan, Adil Rashid, et al.
Publicado: (2020)

Mavrilimumab for severe COVID-19
por: Pourhoseingholi, Mohamad Amin, et al.
Publicado: (2020)

Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial
por: Cid, Maria C, et al.
Publicado: (2022)

Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis
por: Burmester, Gerd R, et al.
Publicado: (2013)

Mavrilimumab for severe COVID-19 – Authors' reply
por: De Luca, Giacomo, et al.
Publicado: (2020)

Spotlight on mavrilimumab for the treatment of rheumatoid arthritis: evidence to date
por: Crotti, Chiara, et al.
Publicado: (2017)

A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis
por: Weinblatt, Michael E., et al.
Publicado: (2017)

A High Neutrophil-Lymphocyte Ratio Is Associated With Increased Morbidity and Mortality in Patients With Coronavirus Disease 2019
por: King, Alexander H., et al.
Publicado: (2021)

Management and Prevention of Cellular-Therapy-Related Toxicity: Early and Late Complications
por: Mucha, Simon R., et al.
Publicado: (2023)

Risk factors associated with development of coinfection in critically Ill patients with COVID-19
por: Orsini, Erica M., et al.
Publicado: (2022)

Mavrilimumab: an evidence based review of its potential in the treatment of rheumatoid arthritis
por: Di Franco, Manuela, et al.
Publicado: (2014)

Model‐Based Discovery and Development of Biopharmaceuticals: A Case Study of Mavrilimumab
por: Wang, Bing, et al.
Publicado: (2017)

Tocilizumab in Coronavirus Disease 2019-Related Critical Illness: A Propensity Matched Analysis
por: Rajendram, Prabalini, et al.
Publicado: (2021)

Neutrophil Extracellular Traps and Cardiovascular Diseases: An Update
por: Bonaventura, Aldo, et al.
Publicado: (2020)

Mashes to Mashes, Crust to Crust. Presenting a novel microstructural marker for malting in the archaeological record
por: Heiss, Andreas G., et al.
Publicado: (2020)

Blood Hyperviscosity: A Novel Link Between Hyperinflammation and Hypercoagulability in COVID-19
por: Bonaventura, Aldo, et al.
Publicado: (2022)

Double-blind randomized proof-of-concept trial of canakinumab in patients with COVID-19 associated cardiac injury and heightened inflammation
por: Cremer, Paul C, et al.
Publicado: (2021)

Canakinumab to reduce deterioration of cardiac and respiratory function in SARS‐CoV‐2 associated myocardial injury with heightened inflammation (canakinumab in Covid‐19 cardiac injury: The three C study)
por: Sheng, Calvin C, et al.
Publicado: (2020)

Clinical Presentation and Outcomes of Acute Pericarditis in a Large Urban Hospital in the United States of America
por: Vecchié, Alessandra, et al.
Publicado: (2020)

Hyperinflammation, T cells, and endotoxemia
por: Inoue, Makoto, et al.
Publicado: (2015)

Interleukin-1 and the NLRP3 inflammasome in COVID-19: Pathogenetic and therapeutic implications
por: Potere, Nicola, et al.
Publicado: (2022)

Getting Started With IBM Websphere sMash
por: Lynn, Ronald, et al.
Publicado: (2010)

Effectiveness of Mavrilimumab in Viral Infections Including SARS-CoV-2 Infection - A Brief Review
por: Bhatt, Kinal, et al.
Publicado: (2021)

Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19
por: Bonaventura, Aldo, et al.
Publicado: (2021)

Immunopathology of Hyperinflammation in COVID-19
por: Gustine, Joshua N., et al.
Publicado: (2021)

Blocking GM-CSF receptor α with mavrilimumab reduces infiltrating cells, pro-inflammatory markers and neoangiogenesis in ex vivo cultured arteries from patients with giant cell arteritis
por: Corbera-Bellalta, Marc, et al.
Publicado: (2022)

Mash1 efficiently reprograms rat astrocytes into neurons
por: Ding, Daofang, et al.
Publicado: (2014)

Crumbled or mashed feed had no significant effect on the performance of lactating sows or their offspring
por: Kim, S. C., et al.
Publicado: (2015)

Pharmacological Inhibition of IKK to Tackle Latency and Hyperinflammation in Chronic HIV-1 Infection
por: Ezeonwumelu, Ifeanyi Jude, et al.
Publicado: (2022)

Kawasaki-Erkrankung oder Hyperinflammations-Syndrom?
Publicado: (2020)

Kawasaki-Erkrankung oder Hyperinflammations-Syndrom?
por: -, -
Publicado: (2020)

Management of hyperinflammation in COVID-19 patients
por: Suberviola, Borja, et al.
Publicado: (2022)

The Potential of Targeting Brain Pathology with Ascl1/Mash1
por: Tang, Bor Luen
Publicado: (2017)

Acute Effects of Liothyronine Administration on Cardiovascular System and Energy Metabolism in Healthy Volunteers
por: Chen, Shanshan, et al.
Publicado: (2022)

Interleukin-1 and the NLRP3 Inflammasome in Pericardial Disease
por: Vecchié, Alessandra, et al.
Publicado: (2021)

Ascl1 (Mash1) Knockout Perturbs Differentiation of Nonneuronal Cells in Olfactory Epithelium
por: Krolewski, Richard C., et al.
Publicado: (2012)

Mash: fast genome and metagenome distance estimation using MinHash
por: Ondov, Brian D., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_79o9lojdnjojsv6luu7n72qimf